137 related articles for article (PubMed ID: 37247914)
21. The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells.
Sennoune SR; Nelius T; Jarvis C; Pruitt K; Kottapalli KR; Filleur S
PLoS One; 2020; 15(6):e0234078. PubMed ID: 32484838
[TBL] [Abstract][Full Text] [Related]
22. Role of DNA Methylation in Cabazitaxel Resistance in Prostate Cancer.
Ramachandran K; Speer C; Nathanson L; Claros M; Singal R
Anticancer Res; 2016 Jan; 36(1):161-8. PubMed ID: 26722040
[TBL] [Abstract][Full Text] [Related]
23. DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
Chao OS; Goodman OB
Prostate; 2021 Oct; 81(14):1032-1048. PubMed ID: 34297853
[TBL] [Abstract][Full Text] [Related]
24. Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1.
Li X; Han X; Wei P; Yang J; Sun J
Cancer Biol Ther; 2020 May; 21(5):452-462. PubMed ID: 32089062
[TBL] [Abstract][Full Text] [Related]
25. CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer.
Li Y; Mizokami A; Izumi K; Narimoto K; Shima T; Zhang J; Dai J; Keller ET; Namiki M
Prostate; 2010 Jan; 70(1):48-60. PubMed ID: 19725034
[TBL] [Abstract][Full Text] [Related]
26. Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner.
Wu F; Lin Y; Cui P; Li H; Zhang L; Sun Z; Huang S; Li S; Huang S; Zhao Q; Liu Q
Cancer Chemother Pharmacol; 2018 Jun; 81(6):999-1006. PubMed ID: 29605876
[TBL] [Abstract][Full Text] [Related]
27. Fatty acid binding protein 5 regulates docetaxel sensitivity in taxane-resistant prostate cancer cells.
Hillowe A; Gordon C; Wang L; Rizzo RC; Trotman LC; Ojima I; Bialkowska A; Kaczocha M
PLoS One; 2023; 18(10):e0292483. PubMed ID: 37796964
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of claspin promotes docetaxel resistance and is associated with prostate-specific antigen recurrence in prostate cancer.
Babasaki T; Sentani K; Sekino Y; Kobayashi G; Thang Pham Q; Katsuya N; Akabane S; Taniyama D; Hayashi T; Shiota M; Oue N; Teishima J; Matsubara A; Yasui W
Cancer Med; 2021 Aug; 10(16):5574-5588. PubMed ID: 34240817
[TBL] [Abstract][Full Text] [Related]
29. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
van Soest RJ; de Morrée ES; Kweldam CF; de Ridder CMA; Wiemer EAC; Mathijssen RHJ; de Wit R; van Weerden WM
Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of cytokeratin 18 is associated with paclitaxel‑resistance and tumor aggressiveness in prostate cancer.
Yin B; Zhang M; Zeng Y; Li Y; Zhang C; Getzenberg RH; Song Y
Int J Oncol; 2016 Apr; 48(4):1730-6. PubMed ID: 26892177
[TBL] [Abstract][Full Text] [Related]
31. CCL2 increases αvβ3 integrin expression and subsequently promotes prostate cancer migration.
Lin TH; Liu HH; Tsai TH; Chen CC; Hsieh TF; Lee SS; Lee YJ; Chen WC; Tang CH
Biochim Biophys Acta; 2013 Oct; 1830(10):4917-27. PubMed ID: 23845726
[TBL] [Abstract][Full Text] [Related]
32. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
[TBL] [Abstract][Full Text] [Related]
33. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.
Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y
Int J Biochem Cell Biol; 2013 Dec; 45(12):2736-48. PubMed ID: 24076216
[TBL] [Abstract][Full Text] [Related]
34. Berbamine targets cancer stem cells and reverses cabazitaxel resistance via inhibiting IGF2BP1 and p-STAT3 in prostate cancer.
Wang L; Lyu C; Stadlbauer B; Buchner A; Nößner E; Pohla H
Prostate; 2024 Feb; 84(2):131-147. PubMed ID: 37828768
[TBL] [Abstract][Full Text] [Related]
35. RNAi targeting of CCR2 gene expression induces apoptosis and inhibits the proliferation, migration, and invasion of PC-3M cells.
Gao J; Wang A; Zhang M; Li H; Wang K; Han Y; Wang Z; Shi C; Wang W
Oncol Res; 2013; 21(2):73-82. PubMed ID: 24406043
[TBL] [Abstract][Full Text] [Related]
36. Estrogen promotes progression of hormone-dependent breast cancer through CCL2-CCR2 axis by upregulation of Twist via PI3K/AKT/NF-κB signaling.
Han R; Gu S; Zhang Y; Luo A; Jing X; Zhao L; Zhao X; Zhang L
Sci Rep; 2018 Jun; 8(1):9575. PubMed ID: 29934505
[TBL] [Abstract][Full Text] [Related]
37. Activation of the
Lombard AP; Lou W; Armstrong CM; D'Abronzo LS; Ning S; Evans CP; Gao AC
Mol Cancer Ther; 2021 Oct; 20(10):2061-2070. PubMed ID: 34326198
[TBL] [Abstract][Full Text] [Related]
38. The chemokine (CCL2-CCR2) signaling axis mediates perineural invasion.
He S; He S; Chen CH; Deborde S; Bakst RL; Chernichenko N; McNamara WF; Lee SY; Barajas F; Yu Z; Al-Ahmadie HA; Wong RJ
Mol Cancer Res; 2015 Feb; 13(2):380-90. PubMed ID: 25312961
[TBL] [Abstract][Full Text] [Related]
39. Polymeric Micellar Delivery of Novel Microtubule Destabilizer and Hedgehog Signaling Inhibitor for Treating Chemoresistant Prostate Cancer.
Yang R; Chen H; Guo D; Dong Y; Miller DD; Li W; Mahato RI
J Pharmacol Exp Ther; 2019 Sep; 370(3):864-875. PubMed ID: 30996033
[TBL] [Abstract][Full Text] [Related]
40. Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy.
Chu CY; Lee YC; Hsieh CH; Yeh CT; Chao TY; Chen PH; Lin IH; Hsieh TH; Shih JW; Cheng CH; Chang CC; Lin PS; Huang YL; Chen TM; Yen Y; Ann DK; Kung HJ
Theranostics; 2021; 11(8):3624-3641. PubMed ID: 33664852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]